Computational insights into taxifolin's therapeutic mechanisms for Alzheimer’s disease
DOI:
https://doi.org/10.69857/joapr.v14i2.1182Keywords:
Taxifolin, Alzheimer’s, Lipinski’s, Network pharmacology, molecular simulationAbstract
Background: Alzheimer's disease (AD) poses a significant challenge for research. Taxifolin is a natural flavonoid and has potential in protecting against Alzheimer’s by inhibiting oxidative stress. This study aims to elucidate the multi-target effects of Taxifolin on Alzheimer’s disease by computational techniques. Materials and Methods: The target genes were mapped into a PPI network using the STRING database. Hub genes were identified using Cytoscape software. Gene Ontology and KEGG pathway analyses were performed to identify AD-related pathways. Finally, docking analysis was performed using CDOCKER and Autodock, and GROMACS molecular dynamics simulations were performed to study the ligand's behaviour. Results and Discussion: The results revealed promising drug-like properties, as assessed by Lipinski’s rule and ADMET predictions. A total of 47 human genes showed significant similarity (≥ 0.70), with 10,234 targets linked to Alzheimer’s disease. Of these, 673 genes were highly associated with the disease (GDA > 0.1). A Venn diagram identified 16 overlapping genes, including BACE1, DPP4, PIK3CA, MTOR, ESR2, and APP. Network analysis revealed interactions among Taxifolin, MTOR, SERPINE1, ESR2, PIK3CA, and NOS3. Taxifolin docking against Alzheimer’s targets identified 5T4B as the best hit, with the lowest binding energy in CDOCKER (−43.57 kcal/mol) and AutoDock Vina (−8.8 kcal/mol). A 100-ns MD simulation confirmed a stable 5T4B–taxifolin complex, showing structural stability (RMSD/RMSF), compactness (Rg), solvent exposure (SASA), and persistent hydrogen bonds. MM-PBSA analysis supported strong binding, primarily driven by van der Waals and electrostatic interactions. Conclusion: Hence, the study offers insights into the multi-target mechanisms of Taxifolin against AD.
Downloads
References
Better M, Mapping A. Alzheimer’s disease facts and figures. Alzheimers Dement., 19, 1598–1695 (2023) https://doi.org/10.1002/alz.13809
Zhang XX, Tian Y, Wang ZT, et al. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J. Prev. Alzheimers Dis., 8, 313–321 (2021) https://doi.org/10.14283/jpad.2021.15
Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci., 11, 111–128 (2009) https://doi.org/10.31887/DCNS.2009.11.2/cqiu
Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet, 368, 387–403 (2006) https://doi.org/10.1016/S0140-6736(06)69113-7
Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J. Neurol. Neurosurg. Psychiatry, 75, 828–833 (2004) https://doi.org/10.1136/jnnp.2003.021493
Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer’s disease: an updated meta-analysis from cohort studies. Front. Aging Neurosci., 10, 83 (2018) https://doi.org/10.3389/fnagi.2018.00083
Singh B, Day CM, Abdella S, Garg S. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management. J. Control. Release, 367, 402–424 (2024) https://doi.org/10.1016/j.jconrel.2024.01.047
Debraj Dey, Roy Mukherjee D, Shoeb A, Biswas P, Santra S. A systematic review of Alzheimer’s disease: exploring genetic and environmental risk factors, biomarkers, and future pharmacotherapy for cognitive decline and neurodegeneration. J. Appl. Pharm. Res., 13, 17–35 (2025) https://doi.org/10.69857/joapr.v13i3.929
Liu Y, Shi X, Tian Y, Zhai S, Liu Y, Xiong Z, Chu S. An insight into novel therapeutic potentials of taxifolin. Front. Pharmacol., 14, 1173855 (2023) https://doi.org/10.3389/fphar.2023.1173855
Khan S, Bano N, Ahamad S, John U, Dar NJ, Bhat SA. Excitotoxicity, oxytosis/ferroptosis, and neurodegeneration: emerging insights into mitochondrial mechanisms. Aging Dis., 16, 2504–2543 (2024) https://doi.org/10.14336/AD.2024.0125
Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A guide to in silico drug design. Pharmaceutics, 15, 49 (2023) https://doi.org/10.3390/pharmaceutics15010049
Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol., 152, 9–20 (2007) https://doi.org/10.1038/sj.bjp.0707305
Wu F, Zhou Y, Li L, Shen X, Chen G, Wang X, Liang X, Tan M, Huang Z. Computational approaches in preclinical studies on drug discovery and development. Front. Chem., 8, 726 (2020) https://doi.org/10.3389/fchem.2020.00726
Balagurusamy B, Ganesan V, Gopi V, Ilayaperumal P. Liposomal and nanomaterial-based strategies for targeted Alzheimer’s disease therapy. ACS Omega, 10, 60004–60019 (2025) https://doi.org/10.1021/acsomega.5c05391
Asil SM, Ahlawat J, Barroso GG, Narayan M. Nanomaterial-based drug delivery systems for the treatment of neurodegenerative diseases. Biomater. Sci., 8, 4109–4128 (2020) https://doi.org/10.1039/D0BM00809E
Published
How to Cite
Issue
Section
Copyright (c) 2026 Ashif Anjukandan, Rajaganapathy Kaliyaperumal

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







